Vor Biopharma Inc
vorbio.comVor Biopharma Inc (NASDAQ: VOR) is a clinical-stage biotechnology company developing engineered cell therapies and targeted medicines for blood cancers and other serious diseases. The company generates no product revenue, funding operations entirely through equity and debt financing, including a $50.0 million warrant sale to institutional investors in June 2025 and a $75.0 million private placement of common stock at $14.05 per share agreed on March 26, 2026. Research and development expenses were $321.5 million for the year ended December 31, 2025, compared to $93.3 million for the year ended December 31, 2024, with the $228.2 million increase driven primarily by in-licensed or acquired program costs. Key programs include telitacicept for generalized myasthenia gravis (gMG) and Sjogren's disease (SjD). Jean-Paul Kress serves as Chief Executive Officer. Vor Biopharma is headquartered in the United States and operates as a non-revenue-generating, pre-commercialization biotechnology company reliant on capital markets to fund its pipeline.
Products & Services
Telitacicept for generalized myasthenia gravis (gMG) and Sjogren's disease (SjD), both in clinical development as of FY2025. Additional product candidates across multiple therapeutic areas are in research and development.
Revenue Model
No product revenue as of the 10-K filed 2026-03-30. Operations are funded through equity issuances, including ATM facility sales via Stifel and private placements to institutional investors, and interest income on cash holdings.
Customers & Markets
No commercial customers as of the 10-K filed 2026-03-30. Target end markets are patients with blood cancers and autoimmune diseases, including gMG and SjD.
Geographic Exposure
Headquartered in the United States. Subject to EU GDPR, UK GDPR, and China PIPL data privacy obligations, indicating some international research or data operations, but primary operations are U.S.-based as of the 10-K filed 2026-03-30.
Financial Snapshot
Loading...
